Inactive Instrument

Highlights Luye Pharma Group Ltd Singapore S.E.

Equities

LUYE

BMG5722Z1014

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Luye Pharma Secures Chinese Medical Regulatory Approval for Parkinson’s Disease Treatment	06-21	MT
Luye Pharma Group Ltd. Announces Its Jinyouping ® (Rotigotine Microspheres for Injection, Ly03003) Developed by the Group Has Been Approved	06-20	CI
Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China	06-11	CI
Luye Pharma's Japanese Partner Towa Files New Drug Application for Dementia Patch	06-06	MT
Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	03-07	CI
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610	03-04	CI
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States	02-01	CI
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval	12-13	MT
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong	12-12	CI
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	12-04	MT
Luye Pharma Group Ltd. Announces Rivastigmine Twice Weekly Transdermal Patch Approval for Marketing in China	31/10/23	CI
Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder	09/10/23	CI
Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio	07/09/23	CI
Luye Pharma Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23	CI
Luye Pharma Group Ltd. Submits New Drug Application for Lurbinectedin	21/08/23	CI
Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United States	17/08/23	CI
Chinese Regulator Accepts Luye Pharma's New Drug Application for Parkinson's Disease Injectable	02/08/23	MT
Luye Pharma Group Ltd. Announces Acceptance of the NDA and Priority Review for Rotigotine Extended-Release Microspheres for Injection by National Medical Products Administration	01/08/23	CI
Luye Pharma Group Ltd. Completes Patient Enrollment for the Phase 2 Clinical Trial of New Class 1 Drug LY03014 in China	06/07/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Luye Pharma Group Ltd Singapore S.E.

Equities

LUYE

BMG5722Z1014

Highlights

Filters